CHOLINERGIC TRANSMISSION

Site of action Type of action Drugs

Muscarinic Agonist a. Carbachol
Drug affecting Muscarinic b. Acetylcholine
(Parasympathomimitic)
and Nicotinic receptor c. Methacholine
d. Muscarine
e. Bethanechol
f. Pilocarpine
g. Oxotremorine
h. Cevimeline

Muscarinic Antagonist a. Atropine

(Parasympatholytic) b. Hyoscine
c. Hyoscine butylbromide
d. Ipratropium
e. Pirenzepine
f. Tiotropium
g. Tropicamide
h. Cyclopentolate
i. Darifenacin

Nicotinic Agonist a. Nicotine

b. Suxamethonium
c. Decamethonium
d. Lobeline
e. Epibatidine
f. Varenicline

Nicotinic Antagonist a. Tubocurarine

b. Atracurium

Ganglion-Stimulating a. Nicotine
Drug affecting Autonomic b. Dimethylphenyl-piperazinium
Ganglia Drug (DMPP)

Ganglion-Blocking a. Hexamethonium
b. Tubocurarine
Drug c. Trimetaphan
d. Pancuronium
e. Atracurium
f. Vecuronium

Depolarizing a. Suxamethonium
Neuromuscular blocking drug b. Succinylcholine
Blocking Agent (Antagonist)

Non-depolarizing a. Tubocurarine
b. Mivacurium
Blocking Agent (Persistant) c. Pancuronium
d. Rocuronium
e. Vecuronium

Short-Acting Cholinesterase a. Endorphium

Drugs that enhance cholinergic
transmission inhibitors
Intermediate-Acting a. Carbamates
Cholinesterase inhibitors b. Neostigmine

Long-Acting/Irreversible a. Organophosphate
Cholinesterase inhibitors b. Parathion